STOCK TITAN

Plus Therapeutics Inc - PSTV STOCK NEWS

Welcome to our dedicated news page for Plus Therapeutics (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on Plus Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Plus Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Plus Therapeutics's position in the market.

Rhea-AI Summary
Plus Therapeutics, Inc. (PSTV) will report Q4 and full year 2023 financial results on March 5, 2024, after market close. The management team will host a conference call and webcast to discuss the results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.01%
Tags
earnings
-
Rhea-AI Summary
Plus Therapeutics, Inc. (Nasdaq: PSTV) announced that it received $3.3M in grant revenue in Q4 2023 and forecasts an additional $6.9M of grant revenue for 2024. The company also entered into a debt restructuring deal with Pershing Capital to reduce 2024 cash burn by $3.7M. The grant funds are advances on future spend and received based on hitting certain milestones. The company believes that the award payment together with its cash on hand provide sufficient runway to fund operations to the second half of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.66%
Tags
none
-
Rhea-AI Summary
Plus Therapeutics, Inc. (PSTV) partners with K2bio to implement novel CSF cancer testing modalities, with initial testing panel available in Q1 2024 for ReSPECT-LM patients. The Company expects testing costs to be partially covered under a grant from The Cancer Prevention and Research Institute of Texas (CPRIT). Plus' tumor cell and molecular biomarker analysis in the ReSPECT-LM Phase 1 trial has shown promise, with an average 53% reduction in CSF tumor cells 28 days after treatment. The FDA has granted Fast Track designation to the treatment, and the program is funded in part by a $17.6 million grant from CPRIT.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.9%
Tags
partnership
Rhea-AI Summary
Plus Therapeutics, Inc. (PSTV) announced that its CEO will present at the 5th Targeted Radiopharmaceuticals Summit Europe in Berlin, Germany. The presentation will focus on Re-186 Radiolabelled NanoLiposomes for Rare Brain and Spinal Cord Tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.56%
Tags
conferences
-
Rhea-AI Summary
Plus Therapeutics, Inc. (Nasdaq: PSTV) announced positive data from the ongoing ReSPECT-GBM Phase 2 trial evaluating rhenium (186Re) obisbemeda for recurrent glioblastoma (rGBM). The study showed a median overall survival of 13 months, a 63% improvement over the current standard of care. Median progression-free survival was 11 months, with favorable safety and imaging data. The company will host a virtual KOL webinar to discuss the data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-27.76%
Tags
clinical trial
-
Rhea-AI Summary
Plus Therapeutics, Inc. (Nasdaq: PSTV) will host a virtual KOL event to discuss new Phase 2 ReSPECT-GBM data in recurrent glioblastoma presented at the Society for NeuroOncology (SNO) Conference. The event will feature presentations from neuro-oncology expert Andrew Brenner, M.D., Ph.D., and neurosurgeons Toral Patel, M.D., and John Floyd, M.D., discussing the unmet need and current treatment landscape for patients with rGBM, the potential of rhenium (186Re) obisbemeda in rGBM, and key highlights from the new Phase 2 data presented at SNO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.43%
Tags
conferences clinical trial
Rhea-AI Summary
Plus Therapeutics, Inc. has received Orphan Drug Designation from the FDA for rhenium (186Re) obisbemeda, a radiotherapeutic candidate for the treatment of breast cancer with leptomeningeal metastases (LM). This designation grants certain benefits to the company, including assistance in drug development, tax credits, and marketing exclusivity. The drug is currently being evaluated in the ReSPECT-LM Phase 1/2a clinical trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.65%
Tags
clinical trial
-
Rhea-AI Summary
Plus Therapeutics, Inc. (Nasdaq: PSTV) has announced a share repurchase program, with authorization to repurchase up to $500,000 of the Company's outstanding common stock. The repurchases will be funded with available cash and will be made based on market conditions and other factors over the next 12 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.74%
Tags
buyback
-
Rhea-AI Summary
Plus Therapeutics, Inc. announced new survival data from the Phase 2 ReSPECT-GBM trial and completion of dosing in Cohort 4 of the Phase 1 ReSPECT-LM trial. The company expects to receive an additional $10.2 million from the CPRIT grant. Current cash balance is $11 million. Management will host a conference call today at 5:00 p.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.74%
Tags
earnings
Rhea-AI Summary
Plus Therapeutics to present updates on the ReSPECT-GBM Trial at SNO Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.34%
Tags
conferences
Plus Therapeutics Inc

Nasdaq:PSTV

PSTV Rankings

PSTV Stock Data

9.00M
4.46M
1.42%
3.09%
1.03%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Austin

About PSTV

plus therapeutics, inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and manufacture of treatments for cancer and other diseases. its lead product candidate is doceplus, a protein-stabilized pegylated liposomal formulation of docetaxel for the treatment of small cell lung cancer. the company is also involved in developing doxoplus, a generic pegylated liposomal encapsulated doxorubicin to treat breast and ovarian cancer, multiple myeloma, and kaposi's sarcoma. it has a license agreement with nanotx, corp. to develop and commercialize nanotx's glioblastoma treatment. the company was formerly known as cytori therapeutics, inc. and changed its name to plus therapeutics, inc. in july 2019. plus therapeutics, inc. was founded in 1996 and is headquartered in austin, texas.